Impact of Portal Vein Thrombosis on Endoscopic Variceal Band Ligation in Liver Cirrhosis
Table 2
Patients baseline characteristics.
Cirrhosis without PVT （N%）
Cirrhosis with PVT （N%）
value
N
126
18
Age (year)
54.79 ± 11.15
53.39 ± 12.61
0.63
Male gender
85 (67.46)
12 (66.67)
0.95
Etiology
Viral
76 (60.32)
7 (38.89)
0.05
Alcoholic
21 (16.67)
2 (11.11)
Other
29 (23.02)
9 (50.00)
Prophylaxis
Primary
7 (5.47)
0
0.31
Secondary
119 (92.97)
18 (100)
Child-Pugh class
A
79 (62.70)
12 (66.67)
0.74
B
47 (37.30)
6 (33.33)
C
0
0
Child-Pugh score
6.20 ± 1.11
6.10 ± 1.02
0.75
MELD score
9.53 ± 2.11
9.67 ± 1.91
0.80
Esophageal varices
G1
0
0
0.74
G2
11 (8.73)
2 (11.11)
G3
115 (91.27)
16 (88.89)
NSBB use
23 (18.25)
3 (16.67)
0.87
Hemoglobin (g/dl)
9.29 ± 2.40
8.48 ± 2.42
0.19
Platelets (×1000/mm3)
68.14 ± 38.18
66.83 ± 33.85
0.89
Creatinine (mg/dl)
0.80 ± 0.21
0.85 ± 0.19
0.33
PT (s)
13.85 ± 1.59
13.91 ± 1.67
0.90
INR
1.21 ± 0.14
1.23 ± 0.16
0.72
Albumin (g/dl)
3.66 ± 0.54
3.78 ± 0.45
0.36
Bilirubin (mg/dl)
1.15 ± 0.76
1.10 ± 0.54
0.78
D-dimer (μg/L)
1539.72 ± 1659.62
3513.61 ± 4370.17
<0.001
None of the patients with PVT are given anticoagulant therapy. PVT: portal vein thrombosis; MELD: the model for end-stage liver disease; NSBB: nonselective beta blockers; PT: prothrombin time; INR: international normalized ratio.
